Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Assets (2016 - 2025)

Capricor Therapeutics has reported Assets over the past 15 years, most recently at $355.9 million for Q4 2025.

  • Quarterly results put Assets at $355.9 million for Q4 2025, up 108.79% from a year ago — trailing twelve months through Dec 2025 was $355.9 million (up 108.79% YoY), and the annual figure for FY2025 was $355.9 million, up 108.79%.
  • Assets for Q4 2025 was $355.9 million at Capricor Therapeutics, up from $126.4 million in the prior quarter.
  • Over the last five years, Assets for CAPR hit a ceiling of $355.9 million in Q4 2025 and a floor of $37.2 million in Q3 2023.
  • Median Assets over the past 5 years was $53.9 million (2022), compared with a mean of $85.6 million.
  • Biggest five-year swings in Assets: plummeted 31.11% in 2023 and later surged 248.95% in 2025.
  • Capricor Therapeutics' Assets stood at $41.3 million in 2021, then increased by 21.21% to $50.1 million in 2022, then grew by 17.25% to $58.7 million in 2023, then skyrocketed by 190.26% to $170.5 million in 2024, then surged by 108.79% to $355.9 million in 2025.
  • The last three reported values for Assets were $355.9 million (Q4 2025), $126.4 million (Q3 2025), and $133.6 million (Q2 2025) per Business Quant data.